



François Blouin, MD

Manna Quebec

1190 A, Rue de Courchevel, Local 203, Lévis, Québec, G6W 0M5, Canada

Tel (418) 839-8572

CURRICULUM VITAE

Education, Certificates and Training

2018-2020	ICH-GCP Training	TransCelerate
Feb 2019	RCR/DEA Certificate	Canadian Red Cross, Québec QC
1991	Doctor of Medicine	Montreal University, Montréal QC
1984	Bachelor of Psychology	Laval University, Québec QC

Professional Activities

2014-Present	Principal Investigator / Sub-Investigator	LMC Clinical Research Inc., Manna Research
2005-2014	Principal Investigator / Sub-Investigator	Pro-Recherche Inc., Saint-Romuald QC
2004-2006	General Practice	Polyclinique des Ponts, Saint-Romuald QC
1999-2006	General Practice	Clinic, St-Prosper QC
1991-2001	Emergency	Port-Cartier QC

Clinical Trials & Research Activities

2016-2020	AC-080A201 (Actelion), D168C00005 (AstraZeneca), B4801010 (Pfizer), 14NMHB (KGK), PT010005 (Pearl Therapeutics), Es0001-C302 (Estetra), MK-0431-848 (Merck), SL75.14 (Stallergens), EFC14834 (Sanofi), 178-MA-1005 (Astellas), CLIK066B2201 (Novartis), ERC-242 (Endoceutics), D5670C00004 (AstraZeneca), PBI-4050-CT-9-08 (Prometic), Sci-B-Vac-002 (VBI), 64565111OBE2001 (Janssen), CEMA401A2201 (Novartis), IXA-CSP-001 (IXALTIS), EFC14828 (Sanofi), ERC-245 (Endoceutics), CP-PRO-QVLP-014 (Medicago), I8F-MC-GPGM (Eli Lilly), EX9536-4388 (Novo Nordisk), 20170625 (Amgen), I8F-MC-GPGL (Eli Lilly), RTB-101-205 (Restorbio), C3421005 (Pfizer), 2693-CL-0304 (Astellas), 2693-CL-0302 (Astellas), ATB-346-P2B-DRF (Antibe), etc.
2015	B1521022 (Pfizer), B1481020 (Pfizer), 28431754DIA3008 (Janssen) 28431754DIA4003 (Janssen), TH005 (Circassia), BMT-301 (Palatin Technologies), 178-CL-101 (Astellas), 178-CL-102 (Astellas), GLARGL07496 (Sanofi), 20120296 (AMGEN), D5895C00001 (AstaZeneca), ADP356-G000401 (Eisai), 15913A (Lundbeck), TVX-01 (TherapeuticsMD), SP304203-00 (Synergy), SP304203-01 (Synergy), 00080 (Ferring), 00081 (Ferring), ITCA-650-CLP-105 (Intarcia), ITCA-650-CLP-107 (Intarcia), MK-8237-001-11 P05607 (Merck), NN2211-4059 (Novo Nordisk), NN1218-3853 (Novo Nordisk), B1971016 (Pfizer), EFC12405 (Sanofi), EFC12703 (Sanofi), SPC-SER120-DB4201301 (Serenity)
Past Research Experience	> 50 clinical trials: Diabetes type 2, vaccine, COPD, women's health, hypogonadism, gastroenterology, zoster pain, chronic pain, hypertension, depression, cardiovascular disease, allergy, asthma